Trophoblastic neoplasms most frequently harbor alterations in TP53, KMT2D, RAD52, KDM5A, and ETV6 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RAD52 Amplification, and KMT2D Mutation are the most common alterations in trophoblastic neoplasm .
There is 1 clinical trial for trophoblastic neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains trophoblastic neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
Nilotinib and paclitaxel are the most common interventions in trophoblastic neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.